Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

BACKGROUND: NSABP B-40 was a 3 × 2 factorial trial testing whether adding capecitabine or gemcitabine to docetaxel followed by doxorubicin plus cyclophosphamide neoadjuvant chemotherapy would improve outcomes in women with operable, HER2-negative breast cancer and whether adding neoadjuvant plus adj...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet Oncol
Hoofdauteurs: Bear, Harry D, Tang, Gong, Rastogi, Priya, Geyer, Charles E, Liu, Qing, Robidoux, André, Baez-Diaz, Luis, Brufsky, Adam M, Mehta, Rita S, Fehrenbacher, Louis, Young, James A, Senecal, Francis M, Gaur, Rakesh, Margolese, Richard G, Adams, Paul T, Gross, Howard M, Costantino, Joseph P, Paik, Soonmyung, Swain, Sandra M, Mamounas, Eleftherios P, Wolmark, Norman
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624323/
https://ncbi.nlm.nih.gov/pubmed/26272770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(15)00041-8
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items